Adjuvant osimertinib, a third‐generation EGFR‐TKI, has recently been demonstrated to provide longer disease‐free survival in patients with resected stage I to III EGFR‐mutated NSCLC over placebo.32 This evidence concerns the gene EGFR and non-small cell lung carcinoma.